- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 91,800 | 16.07.24 17:35:35 | -0,440 | -0,48% | 0,000 | 0,000 | 92,350 | 92,240 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.093,280 | 16.07.24 20:30:52 | +11,170 | +1,03% | 1.092,230 | 1.094,360 | 1.097,290 | 1.082,110 |
